NYSE:MMS - Get Free Report )'s share price hit a new 52-week high during trading on Thursday following a stronger than expected earnings report. The company traded as high as $90.65 and last traded at $86.84, with a volume of 129452 shares. The stock had previously closed at $84.12.
Get Maximus alerts:
Sign Up
The health services provider reported $1.57 EPS for the quarter, beating analysts' consensus estimates of $1.31 by $0.26. Maximus had a return on equity of 15.68% and a net margin of 3.73%. The firm had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.29 billion. During the same quarter in the prior year, the firm earned $0.80 EPS. Maximus's quarterly revenue was up 11.7% on a year-over-year basis.
Maximus Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, May 31st. Investors of record on Wednesday, May 15th will be paid a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 1.43%. The ex-dividend date of this dividend is Tuesday, May 14th. Maximus's payout ratio is 39.74%.
Wall Street Analyst Weigh In Separately, StockNews.com raised shares of Maximus from a "hold" rating to a "buy" rating in a research report on Thursday, February 8th.
Check Out Our Latest Analysis on Maximus
Insider Buying and Selling In related news, CFO David Mutryn sold 8,000 shares of Maximus stock in a transaction on Friday, February 16th. The stock was sold at an average price of $83.95, for a total value of $671,600.00. Following the transaction, the chief financial officer now owns 5,124 shares in the company, valued at $430,159.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink . 1.40% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Maximus A number of hedge funds have recently made changes to their positions in MMS. FMR LLC lifted its position in Maximus by 6.4% during the 3rd quarter. FMR LLC now owns 8,588,189 shares of the health services provider's stock worth $641,366,000 after acquiring an additional 514,698 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Maximus by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 6,062,856 shares of the health services provider's stock worth $508,431,000 after purchasing an additional 69,873 shares in the last quarter. Van Berkom & Associates Inc. boosted its stake in shares of Maximus by 22.3% in the third quarter. Van Berkom & Associates Inc. now owns 1,124,238 shares of the health services provider's stock valued at $83,958,000 after purchasing an additional 204,796 shares during the period. Dimensional Fund Advisors LP grew its holdings in Maximus by 8.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,062,173 shares of the health services provider's stock valued at $89,075,000 after purchasing an additional 79,729 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in Maximus by 1.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 722,227 shares of the health services provider's stock worth $53,936,000 after buying an additional 12,825 shares during the period. Hedge funds and other institutional investors own 97.21% of the company's stock.
Maximus Price Performance The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.71. The company's 50 day moving average is $82.34 and its 200-day moving average is $81.63. The stock has a market cap of $5.11 billion, a PE ratio of 27.74 and a beta of 0.72.
Maximus Company Profile (
Get Free Report )
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
Featured Articles Before you consider Maximus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.
While Maximus currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
